Mapping an enzyme offers clues to treating rare genetic disease
Researchers at the Icahn School of Medicine at Mount Sinai have mapped an enzyme that could be targeted to develop new treatments for glutaric aciduria type 1 (GA1), a rare genetic disorder that can lead to brain damage, revealing new details about how the enzyme works and how its activity is controlled. The findings were published in Science Advances.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Can a scent really sharpen your memory? It's complicated
United Kingdom
-
Air pollution exposure tied to atopic dermatitis in children
United Kingdom
-
RNA switch lets drugs control gene therapy protein production
United Kingdom
-
Is there an opening for Nvidia's competitors, now that Jensen Huang is out?
United States
-
Personalized therapies for Crohn's and ulcerative colitis may follow from method that identifies harmful gut bacteria
United Kingdom
-
GLP-1s often contain untested additive combinations, study finds
United Kingdom
-
New body map traces origins of complex movements in the brains of mice
United Kingdom
-
AI Adds Capacity. People Don’t Scale the Same Way: Lessons on Sustainable Operations
United States